Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKAG1 | P54619 | 1/20 | 0.37 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.37 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | METAP2 | P50579 | 1/20 | 0.32 |
| ▸ | DHODH | Q02127 | 1/20 | 0.31 |
| ▸ | BRD9 | Q9H8M2 | 2/20 | 0.31 |
| ▸ | BRD7 | Q9NPI1 | 2/20 | 0.31 |
| ▸ | TDO2 | P48775 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.30 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.30 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31748634 | 0.83 | PRKAG1 (0.46) | PRKAG1PRKAA1PRKAB1CYP1A2METAP2 | |
| SCHEMBL31748633 | 0.73 | GRIK1 (0.31) | DHODH | |
| SCHEMBL31748384 | 0.69 | TDO2 (0.54) | PRKAG1PRKAA1PRKAB1TDO2 | |
| SCHEMBL31748523 | 0.69 | PRKAG1 (0.60) | PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL31748607 | 0.69 | PRKAG1 (0.61) | PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL31748527 | 0.69 | PRKAG1 (0.44) | PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL31748380 | 0.67 | BTK (0.41) | PRKAG1PRKAA1PRKAB1DHODHTDO2 | |
| SCHEMBL31748704 | 0.67 | PRKAG1 (0.47) | PRKAG1PRKAA1PRKAB1DHODHTDO2 | |
| SCHEMBL30010160 | 0.64 | PRKAB2 (0.36) | PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL30010001 | 0.64 | PRKAG1 (0.49) | PRKAG1PRKAA1PRKAB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388571-A1 | AMP-ACTIVATED PROTEIN KINASE MODULATOR COMPOUNDS AND USES THEREOF | BIOLEXIS THERAPEUTICS INC (US) | 2025-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388571-A1 | AMP-ACTIVATED PROTEIN KINASE MODULATOR COMPOUNDS AND USES THEREOF | PRKAB2, PRKAB1, PRKAR2B | PRKAG1 6/4885PRKAA1 8/4885PRKAB1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.